Atezolizumab for the treatment of non-small cell lung cancer Journal Article


Authors: Santini, F. C.; Rudin, C. M.
Article Title: Atezolizumab for the treatment of non-small cell lung cancer
Abstract: Introduction: The immune system can restrain or promote cancer development and growth. Antibodies targeting immune checkpoints have revolutionized cancer treatment. Among the best responses have been in non-small cell lung cancer (NSCLC) which is largely caused by chronic exposure to carcinogens; associated with high neoantigen creation and sensitization to immune recognition. Atezolizumab was the first approved antibody that targets the PD-1 ligand (PD-L1). Areas covered: This drug profile article covers the basics of the cancer-immunity cycle and reviews some aspects of innate and adaptive immunology. We discuss the discovery of PD-L1 and PD-L2 while highlight the potential differences in targeting PD-L1 versus PD-1. In addition, we briefly summarized the available pre-clinical and clinical data of atezolizumab use in NSCLC. A special section covers the challenges of PD-L1 immunohistochemistry assay. Expert commentary: PD-1:PD-L1 blockade has taken the lead in the immunotherapeutics field and represents the backbone of developing combination immunotherapies. Atezolizumab represents a step forward in the treatment of advanced NSCLC, nonetheless PD1:PD-L1 blockade in early-stage lung cancer is still a matter of debate. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
Keywords: immunohistochemistry; antineoplastic agents; cancer staging; antineoplastic agent; neoplasm staging; animal; animals; carcinoma, non-small-cell lung; lung neoplasms; lung cancer; pathology; monoclonal antibody; immunology; antibodies, monoclonal; immunotherapy; programmed death 1 ligand 1; programmed death 1 receptor; molecularly targeted therapy; pd-l1; molecular targeted therapy; procedures; humans; human; antagonists and inhibitors; pdcd1 protein, human; programmed cell death 1 receptor; atezolizumab; cd274 protein, human; antigens, cd274
Journal Title: Expert Review of Clinical Pharmacology
Volume: 10
Issue: 9
ISSN: 1751-2433
Publisher: Taylor & Francis Group  
Date Published: 2017-01-01
Start Page: 935
End Page: 945
Language: English
DOI: 10.1080/17512433.2017.1356717
PUBMED: 28714780
PROVIDER: scopus
PMCID: PMC6089509
DOI/URL:
Notes: Article -- Export Date: 4 October 2017 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Charles Rudin
    433 Rudin
  2. Fernando Costa Santini
    16 Santini